• Je něco špatně v tomto záznamu ?

Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer

N. Thorenoor, P. Faltejskova-Vychytilova, S. Hombach, J. Mlcochova, M. Kretz, M. Svoboda, O. Slaby,

. 2016 ; 7 (1) : 622-637.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000921

Grantová podpora
NT13549 MZ0 CEP - Centrální evidence projektů
NT13860 MZ0 CEP - Centrální evidence projektů

We determined expression of 83 long non-coding RNAs (lncRNAs) and identified ZFAS1 to be significantly up-regulated in colorectal cancer (CRC) tissue. In cohort of 119 CRC patients we observed that 111 cases displayed at least two-times higher expression of ZFAS1 in CRC compared to paired normal colorectal tissue (P < 0.0001). By use of CRC cell lines (HCT116+/+, HCT116-/- and DLD-1) we showed, that ZFAS1 silencing decreases proliferation through G1-arrest of cell cycle, and also tumorigenicity of CRC cells. We identified Cyclin-dependent kinase 1 (CDK1) as interacting partner of ZFAS1 by pull-down experiment and RNA immunoprecipitation. Further, we have predicted by bioinformatics approach ZFAS1 to sponge miR-590-3p, which was proved to target CDK1. Levels of CDK1 were not affected by ZFAS1 silencing, but cyclin B1 was decreased in both cell lines. We observed significant increase in p53 levels and PARP cleavage in CRC cell lines after ZFAS1 silencing indicating increase in apoptosis. Our data suggest that ZFAS1 may function as oncogene in CRC by two main actions: (i) via destabilization of p53 and through (ii) interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. However, molecular mechanisms behind these interactions have to be further clarified.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000921
003      
CZ-PrNML
005      
20191029134157.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.5807 $2 doi
024    7_
$a 10.18632/oncotarget.5807 $2 doi
035    __
$a (PubMed)26506418
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Thorenoor, Nithyananda $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic.
245    10
$a Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer / $c N. Thorenoor, P. Faltejskova-Vychytilova, S. Hombach, J. Mlcochova, M. Kretz, M. Svoboda, O. Slaby,
520    9_
$a We determined expression of 83 long non-coding RNAs (lncRNAs) and identified ZFAS1 to be significantly up-regulated in colorectal cancer (CRC) tissue. In cohort of 119 CRC patients we observed that 111 cases displayed at least two-times higher expression of ZFAS1 in CRC compared to paired normal colorectal tissue (P < 0.0001). By use of CRC cell lines (HCT116+/+, HCT116-/- and DLD-1) we showed, that ZFAS1 silencing decreases proliferation through G1-arrest of cell cycle, and also tumorigenicity of CRC cells. We identified Cyclin-dependent kinase 1 (CDK1) as interacting partner of ZFAS1 by pull-down experiment and RNA immunoprecipitation. Further, we have predicted by bioinformatics approach ZFAS1 to sponge miR-590-3p, which was proved to target CDK1. Levels of CDK1 were not affected by ZFAS1 silencing, but cyclin B1 was decreased in both cell lines. We observed significant increase in p53 levels and PARP cleavage in CRC cell lines after ZFAS1 silencing indicating increase in apoptosis. Our data suggest that ZFAS1 may function as oncogene in CRC by two main actions: (i) via destabilization of p53 and through (ii) interaction with CDK1/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. However, molecular mechanisms behind these interactions have to be further clarified.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a apoptóza $x genetika $7 D017209
650    _2
$a western blotting $7 D015153
650    _2
$a proteinkinasa CDC2 $x genetika $x metabolismus $7 D016203
650    _2
$a Caco-2 buňky $7 D018938
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kolorektální nádory $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a cyklin B1 $x genetika $x metabolismus $7 D056744
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kontrolní body fáze G1 buněčného cyklu $x genetika $7 D059585
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a HCT116 buňky $7 D045325
650    _2
$a buňky HT-29 $7 D019073
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a poly(ADP-ribosa)polymerasy $x genetika $x metabolismus $7 D011065
650    _2
$a vazba proteinů $7 D011485
650    _2
$a RNA interference $7 D034622
650    _2
$a RNA dlouhá nekódující $x genetika $x metabolismus $7 D062085
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vychytilová, Petra, $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, 65653 Brno, Czech Republic. $d 1987- $7 xx0165184
700    1_
$a Hombach, Sonja $u Institute of Biochemistry, Genetics and Microbiology, University of Regensburg, Regensburg, 93053, Germany.
700    1_
$a Mlčochová, Jitka $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. $7 _AN065407
700    1_
$a Kretz, Markus $u Institute of Biochemistry, Genetics and Microbiology, University of Regensburg, Regensburg, 93053, Germany.
700    1_
$a Svoboda, Marek, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, 65653 Brno, Czech Republic. $d 1975- $7 xx0098478
700    1_
$a Slabý, Ondřej, $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, 65653 Brno, Czech Republic. $d 1981- $7 js20030220015
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 1 (2016), s. 622-637
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26506418 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20191029134636 $b ABA008
999    __
$a ok $b bmc $g 1180061 $s 961488
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 1 $d 622-637 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT13549 $p MZ0
GRA    __
$a NT13860 $p MZ0
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace